At the time of writing, Theravance Biopharma Inc [TBPH] stock is trading at $17.91, up 2.17%. An important factor to consider is whether the stock is rising or falling in short-term value. The TBPH shares have gain 1.70% over the last week, with a monthly amount drifted -0.72%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Theravance Biopharma Inc [NASDAQ: TBPH] stock has seen the most recent analyst activity on December 03, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $27. Previously, B. Riley Securities started tracking the stock with Buy rating on September 12, 2025, and set its price target to $28. On August 06, 2024, downgrade downgraded it’s rating to Market Perform and revised its price target to $10 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $21 on April 12, 2024. Evercore ISI downgraded its rating to a In-line. SVB Leerink started tracking with an Outperform rating for this stock on May 23, 2022, and assigned it a price target of $12. In a note dated November 05, 2021, JP Morgan upgraded a Neutral rating on this stock but restated the target price of $12.
For the past year, the stock price of Theravance Biopharma Inc fluctuated between $7.90 and $20.33. Currently, Wall Street analysts expect the stock to reach $33.5 within the next 12 months. Theravance Biopharma Inc [NASDAQ: TBPH] shares were valued at $17.91 at the most recent close of the market. An investor can expect a potential return of 87.05% based on the average TBPH price forecast.
Analyzing the TBPH fundamentals
According to Theravance Biopharma Inc [NASDAQ:TBPH], the company’s sales were 80.33M for trailing twelve months, which represents an 18.51% jump. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -0.41%, Pretax Profit Margin comes in at 0.59%, and Net Profit Margin reading is 0.2%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.08 and Total Capital is -0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.31 points at the first support level, and at 16.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.45, and for the 2nd resistance point, it is at 18.98.
Ratios To Look Out For
It is important to note that Theravance Biopharma Inc [NASDAQ:TBPH] has a current ratio of 9.48. On the other hand, the Quick Ratio is 9.48, and the Cash Ratio is 4.67. Considering the valuation of this stock, the price to sales ratio is 11.30, the price to book ratio is 3.90 and price to earnings (TTM) ratio is 31.84.
Transactions by insiders
Recent insider trading involved Farnum Rhonda, SVP, COMM & MEDICAL AFFAIRS, that happened on Dec 03 ’25 when 31067.0 shares were sold. Officer, RHONDA FARNUM completed a deal on Dec 03 ’25 to buy 31067.0 shares. Meanwhile, Director ERAN BROSHY bought 29501.0 shares on Nov 26 ’25.
